| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2aa388e460f6cf478bd46c925c6ab10e |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 |
| filingDate |
2015-03-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_40e8ff663b7a7c295c64630ce88029e8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aee99dc88d58da8313367e02130c8f0c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7ded0b08775b941950d924a6da9e1d42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_646ccea422ef5112d564fc9caf73b699 |
| publicationDate |
2017-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2017129895-A1 |
| titleOfInvention |
Amorphous form of baricitinib |
| abstract |
The present invention provides an amorphous form of baricitinib, processes for its preparation, a pharmaceutical composition comprising it, and its use for the treatment of JAK-associated diseases. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020072870-A1 |
| priorityDate |
2014-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |